What is the primary management strategy for Kawasaki disease?

The primary management strategy for Kawasaki disease involves the administration of intravenous immunoglobulin (IVIG) and aspirin. This combination is crucial in reducing the risk of serious complications, particularly coronary artery abnormalities that can arise from the inflammation caused by the disease.

IVIG helps to modulate the immune response and has been shown to decrease fever and prevent coronary artery inflammation, reducing the risk of coronary artery aneurysms. Aspirin, on the other hand, acts as both an anti-inflammatory agent and an antiplatelet medication, further protecting against cardiovascular complications. The timing of IVIG administration is particularly important, and it is most effective when given early in the disease course.

Other treatment options, such as antibiotics, topical steroids, and observation alone, do not address the underlying inflammatory process seen in Kawasaki disease and would not be adequate for managing this condition effectively. Therefore, the combination of IVIG and aspirin is the standard and effective approach for treating Kawasaki disease, ensuring better outcomes for affected children.